EBQ:RE-LY: Difference between revisions

Revision as of 00:01, 2 December 2013

incomplete Journal Club Article

Connolly SJ, et al. "Dabigatran versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 2009. 361(12):1139-51.
PubMed Full text PDF

Clinical Question

Is dabigatran (brand name Pradaxa) safe for use in patients with atrial fibrillation when compared to warfarin in terms of stroke and bleeding risks.

Conclusion

In comparison to warfarin in patients with atrial fibrillation, dabigatran given at a dose of 110 mg demonstrated similar stroke and lower bleeding rates. At 150 mg, dabigatran use was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.

Major Points

Inclusion Criteria

Exclusion Criteria

Interventions

Outcome

Primary Outcomes

Secondary Outcomes

Subgroup analysis

Criticisms

Funding

Sources

Authors:

Revision as of 12:19, 25 November 2013 (view source) Ostermayer (talk \| contribs) (→‎Clinical Question) ← Older edit	Revision as of 00:01, 2 December 2013 (view source) Rossdonaldson1 (talk \| contribs) m (Rossdonaldson1 moved page RE-LY to EBQ:RE-LY) Newer edit →
(No difference)